✦ LIBER ✦

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

✍ Scribed by T. H. Han, R. Chen, R. Advani, R. B. Berryman…

Book ID: 120776055
Publisher: Springer
Year: 2013
Tongue: English
Weight: 312 KB
Volume: 72
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-013-2192-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Retreatment with brentuximab vedotin in

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

✍ Bartlett, Nancy L; Chen, Robert; Fanale, Michelle A; Brice, Pauline; Gopal, Ajay 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 336 KB

A Phase I Weekly Dosing Study of Brentux

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

✍ Fanale, M. A.; Forero-Torres, A.; Rosenblatt, J. D.; Advani, R. H.; Franklin, A. 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 267 KB

P959: Clinical and neurophysiological sp

P959: Clinical and neurophysiological spectrum of peripheral neurotoxicity in patients with CD30-positive malignancies, treated with Brentuximab Vedotin

✍ Pastorelli, F.; Plasmati, R.; Salvi, F. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 61 KB